Sunmax Biotechnology Co., Ltd. (TPEX:4728)
Taiwan
· Delayed Price · Currency is TWD 388.50
-6.50 (-1.65%)
Apr 28, 2026, 1:30 PM CST
Sunmax Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,026 | 1,818 | 1,689 | 1,400 | 1,036 | Upgrade
|
| Revenue Growth (YoY) | 11.45% | 7.64% | 20.64% | 35.19% | 21.01% | Upgrade
|
| Cost of Revenue | 437.54 | 339.35 | 284.1 | 207.27 | 141.21 | Upgrade
|
| Gross Profit | 1,589 | 1,479 | 1,405 | 1,193 | 894.45 | Upgrade
|
| Selling, General & Admin | 548.09 | 512.52 | 481.35 | 407.22 | 502.21 | Upgrade
|
| Research & Development | 42.23 | 39.18 | 28.74 | 17.97 | 24.63 | Upgrade
|
| Operating Expenses | 590.32 | 551.7 | 510.1 | 424.8 | 527.08 | Upgrade
|
| Operating Income | 998.31 | 926.96 | 894.8 | 768 | 367.37 | Upgrade
|
| Interest Expense | -4.71 | -5.95 | -2.94 | -1.35 | -2.81 | Upgrade
|
| Interest & Investment Income | 12.17 | 11.24 | 13.2 | 7.18 | 3.79 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.93 | 17.12 | 1.95 | 2.43 | -3.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.3 | 4.84 | 2.51 | 0.46 | -6.23 | Upgrade
|
| EBT Excluding Unusual Items | 1,015 | 954.22 | 909.52 | 776.71 | 359.1 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -0.63 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.43 | -0.49 | -0.13 | 0.46 | -2.1 | Upgrade
|
| Other Unusual Items | - | 0.18 | - | 0.01 | 0.49 | Upgrade
|
| Pretax Income | 1,015 | 953.28 | 909.39 | 777.18 | 357.49 | Upgrade
|
| Income Tax Expense | 288.83 | 273.87 | 283.68 | 243.35 | 111.84 | Upgrade
|
| Earnings From Continuing Operations | 725.75 | 679.41 | 625.71 | 533.83 | 245.64 | Upgrade
|
| Net Income | 725.75 | 679.41 | 625.71 | 533.83 | 245.64 | Upgrade
|
| Net Income to Common | 725.75 | 679.41 | 625.71 | 533.83 | 245.64 | Upgrade
|
| Net Income Growth | 6.82% | 8.58% | 17.21% | 117.32% | 3.18% | Upgrade
|
| Shares Outstanding (Basic) | 54 | 54 | 54 | 54 | 54 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 55 | 55 | 55 | 55 | Upgrade
|
| Shares Change (YoY) | -0.01% | 0.00% | -0.01% | 0.03% | -0.02% | Upgrade
|
| EPS (Basic) | 13.33 | 12.47 | 11.49 | 9.80 | 4.51 | Upgrade
|
| EPS (Diluted) | 13.31 | 12.46 | 11.47 | 9.79 | 4.51 | Upgrade
|
| EPS Growth | 6.82% | 8.63% | 17.16% | 117.07% | 3.20% | Upgrade
|
| Free Cash Flow | 766.31 | 529.07 | 740.9 | 489.99 | -9.74 | Upgrade
|
| Free Cash Flow Per Share | 14.05 | 9.70 | 13.59 | 8.98 | -0.18 | Upgrade
|
| Dividend Per Share | 12.100 | 11.600 | 11.000 | 9.500 | 4.400 | Upgrade
|
| Dividend Growth | 4.31% | 5.46% | 15.79% | 115.91% | 120.00% | Upgrade
|
| Gross Margin | 78.41% | 81.33% | 83.18% | 85.19% | 86.37% | Upgrade
|
| Operating Margin | 49.27% | 50.99% | 52.98% | 54.85% | 35.47% | Upgrade
|
| Profit Margin | 35.82% | 37.37% | 37.05% | 38.13% | 23.72% | Upgrade
|
| Free Cash Flow Margin | 37.82% | 29.10% | 43.87% | 35.00% | -0.94% | Upgrade
|
| EBITDA | 1,070 | 994.7 | 936.47 | 800.67 | 397.3 | Upgrade
|
| EBITDA Margin | 52.80% | 54.71% | 55.45% | 57.19% | 38.36% | Upgrade
|
| D&A For EBITDA | 71.5 | 67.74 | 41.67 | 32.68 | 29.94 | Upgrade
|
| EBIT | 998.31 | 926.96 | 894.8 | 768 | 367.37 | Upgrade
|
| EBIT Margin | 49.27% | 50.99% | 52.98% | 54.85% | 35.47% | Upgrade
|
| Effective Tax Rate | 28.47% | 28.73% | 31.20% | 31.31% | 31.29% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.